ClinicalTrialsFinder
TerminatedPhase 2ACTRN12607000447459

A Phase 1/2 Single Center, Randomized, Double-blind, Placebo-controlled, Left-Right Comparison Study to Evaluate the Safety and Preliminary Efficacy of a Topical Antimicrobial (NEO101) in Older Adolescents and Adults with at least Moderate Atopic Dermatitis

Sponsor

Neosil Inc.

Enrollment

15 participants

Start Date

Sep 10, 2007

Study Type

Interventional

Conditions

Antimicrobial treatment of atopic dermatitis

Summary

The Skin Centre Suite 5 AHC House 14 Carrara Street Benowa, Queensland 4217 Therapeutic Goods Administration CTN Number 2007/490

Eligibility

Sex: Both males and femalesMin Age: 16 YearssMax Age: 50 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests a topical antimicrobial cream (NEO101) for treating atopic dermatitis (eczema) that has a bacterial infection component. It is open to people aged 16 to 50 with mild-to-moderate eczema and positive skin cultures for Staphylococcus aureus. Participants will apply the cream to affected skin areas and have their eczema severity monitored.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Eligible subjects will be randomized to receive both NEO101 0.95% gel and vehicle-containing placebo gel twice daily for 14 days. Treatment (blinded to treatment assignment) will be administered to t

Eligible subjects will be randomized to receive both NEO101 0.95% gel and vehicle-containing placebo gel twice daily for 14 days. Treatment (blinded to treatment assignment) will be administered to the left and right side target skin surface areas for 14 days. A 14-day safety and efficacy assessment period will follow the treatment period.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000447459